Macrogenics (MGNX) Income from Continuing Operations (2012 - 2026)
Macrogenics' (MGNX) quarterly Income from Continuing Operations came in at 38908000.0 in Q1 2026, up 8.91% year-on-year from 35724070.76 in Q1 2025, and down 175.42% on a QoQ basis from 14127000.0 in Q4 2025.
Macrogenics (MGNX) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has 15 years of Income from Continuing Operations data on file, last reported at 38908000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 8.91% year-over-year to 38908000.0 in Q1 2026; TTM through Mar 2026 was 72464000.0, a 26.04% decrease from a year earlier, with the FY2025 full-year figure at 74592000.0, down 11.39% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 38908000.0, down from 14127000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for MGNX reached as high as 56309000.0 in Q3 2024 and fell as low as 100195000.0 in Q1 2024.
- Historically, Income from Continuing Operations has averaged 31213882.35 across 5 years, with a median of 38908000.0 in 2026.
- Across the five-year window, Income from Continuing Operations slumped 511.87% in 2023 and soared 258.61% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 11983000.0 in 2022, then slumped by 511.87% to 49354000.0 in 2023, then surged by 68.75% to 15421000.0 in 2024, then grew by 8.39% to 14127000.0 in 2025, then tumbled by 175.42% to 38908000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 38908000.0 in Q1 2026, 14127000.0 in Q4 2025, and 16822000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Macrogenics | 230.64 Mn | 164.12 Mn | - | -38.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.91 Mn |
| Dec 31, 2025 | -14.13 Mn |
| Sep 30, 2025 | 16.82 Mn |
| Jun 30, 2025 | -36.25 Mn |
| Mar 31, 2025 | -42.72 Mn |
| Dec 31, 2024 | -15.42 Mn |
| Sep 30, 2024 | 56.31 Mn |
| Jun 30, 2024 | -55.66 Mn |
| Mar 31, 2024 | -100.20 Mn |
| Dec 31, 2023 | -49.35 Mn |
| Sep 30, 2023 | -35.50 Mn |
| Jun 30, 2023 | -47.06 Mn |
| Mar 31, 2023 | -46.25 Mn |
| Dec 31, 2022 | 11.98 Mn |
| Sep 30, 2022 | -24.96 Mn |
| Jun 30, 2022 | -41.81 Mn |
| Mar 31, 2022 | -67.54 Mn |
| Dec 31, 2021 | -385.83 Mn |
| Sep 30, 2021 | -72.91 Mn |
| Jun 30, 2021 | -94.21 Mn |